CIK 0000872589 · Large accelerated filer
REGENERON PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- REGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- operating
- EIN
- 133444607
- Phone
- 9148477000
- Business address
- 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
- Former names
- REGENERON PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $51,901,544
- in 11 filings, $8.6M under 10b5-1 plans
Net −$51,901,544. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-09 | SING GEORGE L Director | Sale | −500 | $955.00 | $478K | 26,349 |
| 2024-02-09 | SING GEORGE L Director | Option exercise · Non-Qualified Stock Option (right to buy) | −500 | 9,838 | ||
| 2024-02-09 | Fenimore Christopher R. SVP Finance & CFO | Sale | −344 | $950.49 | $327K | 18,947 |
| 2024-02-09 | Fenimore Christopher R. SVP Finance & CFO | Sale | −487 | $951.39 | $463K | 18,460 |
| 2024-02-09 | Fenimore Christopher R. SVP Finance & CFO | Sale | −1,046 | $952.62 | $996K | 17,414 |
| 2024-02-09 | Fenimore Christopher R. SVP Finance & CFO | Sale | −1,342 | $953.47 | $1.3M | 16,072 |
| 2024-02-09 | Fenimore Christopher R. SVP Finance & CFO | Sale | −1,100 | $954.57 | $1.1M | 14,972 |
| 2024-02-09 | Fenimore Christopher R. SVP Finance & CFO | Sale | −600 | $955.00 | $573K | 14,372 |
| 2024-02-08 | SING GEORGE L Director | Option exercise | +500 | $413.33 | $207K | 26,849 |
| 2024-02-08 | SING GEORGE L Director | Sale | −500 | $945.00 | $473K | 26,349 |
| 2024-02-08 | SING GEORGE L Director | Option exercise · Non-Qualified Stock Option (right to buy) | −500 | 10,338 | ||
| 2024-02-07 | LAROSA JOSEPH J EVP General Counsel and Secret | Sale | −1,000 | $950.00 | $950K | 38,543 |
| 2024-02-07 | STAHL NEIL EVP Research and Development | Sale | −100 | $947.34 | $95K | 59,956 |
| 2024-02-07 | STAHL NEIL EVP Research and Development | Sale | −1,894 | $948.69 | $1.8M | 58,062 |
| 2024-02-07 | STAHL NEIL EVP Research and Development | Sale | −601 | $949.45 | $571K | 57,461 |
| 2024-02-07 | STAHL NEIL EVP Research and Development | Sale | −3,127 | $950.43 | $3.0M | 54,334 |
| 2024-02-07 | STAHL NEIL EVP Research and Development | Sale | −1,237 | $951.49 | $1.2M | 53,097 |
| 2024-02-07 | STAHL NEIL EVP Research and Development | Sale | −1,059 | $952.49 | $1.0M | 52,038 |
| 2024-02-07 | STAHL NEIL EVP Research and Development | Sale | −19 | $953.00 | $18K | 52,019 |
| 2024-02-05 | McCourt Marion EVP Commercial | Sale | −1,000 | $934.71 | $935K | 13,789 |
Page 36 of 49 · 971 trades